Poster Program

1 - Complement and Acute Phase Reactants
1: Complement and Acute Phase Reactants 2: Microglial/Astroglial/Mononuclear Cell Physiology 3: Cytokines 4: Second Messenger and Oxidative Metabolism, Miscellaneous 5: Clinical Mastars, Development of Substances with Potential Therapeutic Effects
1.01	A novel method for mRNA analysis using fixed brain tissues confirms C1q gene expression in the Alzheimer disease brain H Sato1,2*, I Tooyama1, O Yasuhara1, H Kimura1, Y Konishi2, Y Shen2, et al: 1Shiga University of Medical Science, Japan: 2Otowa Hospital, Japan: 3Sun Health Research Institute, USA
1.02	Modulation of complement mediated neuroinflammation in Alzheimer's disease by vaccinia virus complement control protein G J Kotwal*; University of Louisville School of Medicine, USA: D K Lahiri; Indiana University School of Medicine, USA
1.04	Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain R Strohmeyer*, Y Shen, J Rogers; Sun Health Research Institute, USA
1.05	S-100 protein and neuron-specific enolase concentration in serum as useful marker of brain damage in acute stroke J Horvat1*, D Begovic2, V Martic3, A Jovicic3, S Spasic1, D Molosevic1; 1Univ School of Pharmacy, Yugoslavia: 2KBC "Dr Dragisa Misovic", Yugoslavia: 3Military Medical Academy, Thailand
1.06	Amyloidogenic effects of the acute phase protein a 1-antichymotrypsin C R Abraham1*, L Mucke2, E Masliah3, R Yamin1; 1Boston University School of Medicine, USA: 2University of California San Francisco, USA: 3University of California San Diego, USA
1.07	Inflammation modulates b -secretase (BACE) gene expression in hippocampus of APPswe trasgenic mice P Mascarucci1*, J M Long1, C Perego2, M Barba2, D K Ingram1, M G De Simoni2; 1National Institute on Aging, USA: 2Mario Negri Research Institute, Italy
1.08	Apolipoprotein E is required for the maintenance of the integrity of the blood-brain barrier during aging M Mulder1*, E C M de Lange2, A Blokland1, D van den Berg2, A H F Bakker1, D Terwel1, et al; 1University of Maastricht, Netherlands: 2Leiden University, Netherlands: TNO Prevention and Health, Netherlands
2 - Microglial/Astroglial/Mononuclear Cell Physiology
1: Complement and Acute Phase Reactants 2: Microglial/Astroglial/Mononuclear Cell Physiology 3: Cytokines 4: Second Messenger and Oxidative Metabolism, Miscellaneous 5: Clinical Mastars, Development of Substances with Potential Therapeutic Effects
2.01	Ligation of microglial CD40 results in SRC kinase-induced P44/42 MAPK-dependent TNF-a production T Town*, J Tan, D Paris, Y Wu, M Mullan; Roskamp Institute USF, USA
2.02	The CD40-CD40L interaction leads to microglial activation following b -amyloid stimulation J Tan*, T Town, D Paris, T Mori, F Crawford, M Mullan; The Roskamp Institute USF, USA
2.03	Inflammatory resertoire of Alzheimer's disease microglia in culture L-F Lue1*, Y Shen1, R E Rydel2, H Hampel3, G Murphy4, S D Yan5, et al: 1Sun Health Research Inst, USA: 2Elan Pharmaceuticals, USA: 3Ludwig Maximillian Univ, Germany: 4Stanford Univ, USA: 5Columbia Univ, USA
2.04	Internalization of Ab is a critical determinant in stimulating mononuclear phagocyte-mediated neurotoxicity R B Weltzien*, J S Pachter; University of Connecticut Health Center, USA
2.05	a - Crystallin synergizes with b -amyloid to induce microglial activation R Leucken1, K K Shama2, N R Bhat1*; 1Medical University of South Carolina, USA: 2University of Missouri, USA
2.06	Cerebrolysin® reduces microglia activation in vivo and in vitro: a potential neuroprotection mechanism X A Álvarez*, V R M Lombardi, L Fernández Novoa, M García, C Sampedro, A Cagiao, et al; EuroEspes Biomedical Research Centre, Spain: JSW Research Inc, Austria: Ebewe Arzneimittel, Austria
2.07	Regulation of brain immunity: a central role played by a -amyloid and IL-13 on microglial cells V R M Lombardi, X A Álvarez, L Fernández Novoa, M García, C Sampedro, M De Olano, R Cacabelos*; EuroEspes Biomedical Research Center, Spain
2.08	One year "plateau-phase" in neuroglial cell cultures V R M Lombardi*, X A Álvarez, L Fernández Novoa, M De Olano, L Corzo, C Sanpedro, R Cacabelos; EuroEspes Biomedical Research Center, Spain
2.09	Beta-amyloid production and processing in monocytes, astrocytes, epithelial, and endothelial cells lines infected with Chlamydia pneumoniae isolated from AD brains C S Little*, A MacIntyre, C Hammond, D M Appelt, B J Balin; Philadelphia College of Osteopathic Medicine, USA
2.10	Unusual presence of microglia in the subretinal space of albino mice in the absence of inflammatory disease T F Ng*, J W Streilein; Harvard Medical School, USA
2.11	Responses of microglia to b-amyloid of the Alzheimer's and HCHWA-D types may be related to fibril morphology B M Austen*, M F Manca, A K Siam, O M A El-Agnaf; St George's Hospital Medical School, UK
2.12	Generation of microglia specific reagents from peptide libraries: Evaluation of different selection strategies J Aarum1*, K Lundin1, L Appelsved2, J Dypbukt-Kjällman2, K Sandberg2, M A A Persson1, et al; 1Karolinska Institute, Sweden: 2AstraZeneca, Sweden
2.13	Microglial cyclooxygenase expression in Alzheimer's disease J J M Hoozemans1*, J M Rozemuller2, I Janssen1, R Veerhuis1, P Eikelenboom1; 1Academic Hospital Vrije Universiteit Amsterdam, The Netherlands: 2Academic Medical Center Amsterdam, The Netherlands
2.14	Neuronal and astrocytic coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease M T Heneka1,3, H Wiesinger2, L Dumitrescu1, U Wüllner1, P-A Löschmann, T Klockgether1, D L Feinstein3*; 1Univ of Bonn, Germany: 2Univ of Tübingen, Germany: 3Univ of Illinois, USA
2.15	Altered immunological features in lymphocytes from Alzheimer's disease patients K Schindowski1*, L Frölich1, K Maurer1, C Czech2, W E Müller1, A Eckert1, et al: 1University of Frankfurt, Germany: 2Aventis, France
2.16	Alzheimer's peptide-induced toxicity in the retina in vivo: role of glial cells N Marín1, B Romero1*, M Díaz-Llopis2, F Bosch-Morell1, J Romá1: 1University of Valencia, Spain: 2University Hospital La Fe, Spain
2.17	Age- and gender-related differences in total numbers of astrocytes and microglia in hippocampal subregions of C57B1/6 mice P R Mouton*, J M Long, E A Stocks, S Rim, V Howard, D K Ingram; The Johns Hopkins University School of Medicine, USA
2.18	Activated microglia release compounds that potentiate both the AMPA and NMDA subtypes of glutamate currents M R Kasten*, D Giulian, P E Schulz; BCOM, USA
2.19	Corticosterone suppresses the early increase in MCP-1 associated with chemically-induced brain damage but does not suppress accompanying gliosis A R Little*, J P O'Callaghan; National Institute for Occupational Safety and Health, USA
3 - Cytokines
1: Complement and Acute Phase Reactants 2: Microglial/Astroglial/Mononuclear Cell Physiology 3: Cytokines 4: Second Messenger and Oxidative Metabolism, Miscellaneous 5: Clinical Mastars, Development of Substances with Potential Therapeutic Effects
3.01	A tumor necrosis factor haplotype associated with late-onset Alzheimer disease could lead to neuroinflammation - The NIMH Alzheimer Disease Genetics Initiative J S Collins1, R T Perry1, D Blacker2, R E Tanzi2, S S Bassett3, R C P Go1*; 1University of Alabama at Birmingham, USA: 2Massachusetts General Hospital, USA: 3Johns Hopkins University, USA
3.02	Quantification of cytokine mRNA in organotypic hippocampal cultures with TaqMan real-time RT-PCR S P Selwood*, V A M Vincent, G M Murphy; Stanford University School of Medicine, USA
3.03	Apolipoprotein E modulates CNS cytokine expression J Lynch*, D Morgan, J Mance, D T Laskowitz; Duke University Medical Center, USA
3.04	Interleukin-1b - (IL-1b -) modulated gene expression in normal human neural progenitor (NHNP) cell lines using high density cDNA arrays W J Lukiw*, N G Bazan; Louisiana State University School of Medicine, USA
3.06	CC chemokine production of amyloid-b -stimulated primary human macrophages and U373 astrocytes H A Smits*, L A Boven, A Rijsmus, J Verhoef, H S L M Nottet; Eijkman-Winkler Institute, The Netherlands
3.07	Astrocytes as a source of beta amyloid production following exposure to cytokines I Blasko*, M Stampfer-Kountchev, R Veerhuis1, P Eikelenboom1, B Grubeck-Loebenstein; Institute for Biomedical Aging Research, Austria: 1Vrije Universiteit Amsterdam, The Netherlands
3.08	PrP induced interleukin-6 synthesis by adult human microglia is not affected by COX-inhibitors R Veerhuis1*, J J M Hoozemans1, I Janssen1, R S Boshuizen2, J P M Langeveld2, P Eikelenboom1; 1Vrije Universiteit Amsterdam, The Netherlands: 2Institute for Animal Science and Health, The Netherlands
3.09	Differential effects of allele polymorphism in the IL-6 gene on the risk of late onset Alzhemier's disease F Licastro*, S Pedrini, M Bonafè, L M E Grimaldi, F Olivieri, C Franceschi, et al; University of Bologna, Italy
3.10	Age and concentration dependent neurotoxicity and neuroprotection by TNF in cortical neurons from b -amyloid toxicity J J Viel*, D Q McManus, G J Brewer; Southern Illinois University School of Medicine, USA
3.11	TNF-a polymorphism at position (-308) is associated with HLA-DR3 but not Alzheimer's disease D Culpan,* S MacGowan, J M Ford, G K Wilcock; University of Bristol, UK
3.12	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain H Hampel*, M Scheloske, A Haslinger, F Padberg, S J Teipel, C Hulette, H-J Möller; Ludwig-Maximilian University, Germany
3.14	Cycles of iNOS dependent and iNOS independent neuronl loss in hippocampal slice cultures P J Bergold*, S I Moskowitz, S B Basu, SUNY Downstate Medical Center, USA
3.15	IL-1ra gene polymorphisms and AD pathology G H Murdoch*; Oregon Health Sciences University, USA
4 - Second Messenger and Oxidative Metabolism, Miscellaneous
1: Complement and Acute Phase Reactants 2: Microglial/Astroglial/Mononuclear Cell Physiology 3: Cytokines 4: Second Messenger and Oxidative Metabolism, Miscellaneous 5: Clinical Mastars, Development of Substances with Potential Therapeutic Effects
4.01	Oxidative modification of a -Synuclein leading to protein self-oligomerization S R Paik*, H-J Shin, E-K Lee, D Lee, C-S Chang; Inha University, Korea
4.02	LPS-induced neuroinflammatory effects do not recover with time B Hauss-Wegrzyniak*, P D Vraniak, G L Wenk; University of Arizona, USA
4.03	Enhanced neuronal and astroglial expression of the anti-oxidant enzyme NAD(P)H:quinone oxidoreductase (NQO1) in the Alzheimer's disease brain F L Van Muiswinkel1*, J M Rozemuller2, R Veerhuis1, D Siegel3, P J Sherratt4, B Drukarch1; 1Vrije Universiteit, Netherlands: 2Academic Medical Hospital, Netherlands: 3Univ of Colorado, USA: 4University of Dundee, UK
4.04	Inflammatory mechanisms in AD: b -amyloid-stimulated proinflammatory responses and neurotoxicity are blocked by activators of the transcription factor PPARg G Landreth*, C Combs, D Johnson, C Karlo: Case Western Research University, USA
4.05	The dynamic model of fibrillar plaque formation and degradation in human and APPSW transgenic mouse brain J Wegiel*, K-C Wang, H Imaki, A Wronska, M Osuchowski, W J Lipinski, et al; Institute for Basic Research in Developmental Disabilities and Parke-Davies/Warner-Lambert, USA
4.06	Molecular mechanisms and modulation of glial activation: ligand modulation of biological responses mediated by gene-regulating protein kinases L J Van Eldik*, T Koppal, A R Sawkar, S Mirzoeva, T J Lukas, M Hibert, et al; Drug Discovery Program and Northwestern University, USA and IFR G Laustriat, France
4.07	PPARg -agonists prevent cerebellar granule cell death by suppression of inducible nitric oxide synthase expression M T Heneka1,2*, D L Feinstein2, T Klockgether1; 1University of Bonn, Germany: 2University of Illinois, USA
4.08	Oxidative stress and post-translational modification of beta-amyloid L Galeazzi*, P Ronchi, C Franceschi, S Giunta; Laboratorio Analisi Chimico Cliniche-Microbiologia e Diagnostica Molecolare INRCA, Italy
4.09	Activation of contact system by Alzheimer's b -amyloid peptides L Bergamaschini*, L Parnetti1, C Donarini, G Gobbo, A Agostoni; University of Milan, Italy: 1University of Perugia, Italy
4.10	Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase and NF-k B J Ryu, H Pyo, I Jou, E Joe*; Ajou University School of Medicine, Korea
4.11	Expression of macrophage colony stimulating factor receptor is increased in the APPV717F transgenic mouse model of Alzheimer's disease G Murphy*, O Mitrasinovic, F Zhao, L Yang; Stanford University, USA: B Cordell; Scioc Inc, USA
4.12	Analysis of 1184 genes in Alzheimer CA1 hippocampus: synaptic signaling and transcription factor deficits and upregulation of proinflammatory pathways W J Lukiw*, L A Carver, H J LeBlanc, N G Bazan; Louisiana State University, USA
4.13	Oxidative stress, angiogenesis and Alzheimer's disease Y Fang*, M Hu, K Liu; Fudan University, PR China
4.14	Aluminum-induced inflammation and its role in Alzheimer's disease A Campbell*, S C Bondy; University of California Irvine, USA
4.15	Aluminosilicate particulate and beta-amyloid in vitro interactions: a model of Alzheimer plaque formation P Evans*; University of Glasgow, UK: C Harrington; University of Aberdeen, UK
4.17	Level of Ab 1-42 in cerebrospinal fluid of patients with MM-type 1 Creutzfeldt-Jakob disease M Otto*, H Esselmann, W Schulz-Schaeffer, M Neumann, A Schöter, P Ratzka, et al; Universität Göttingen, Germany
4.18	Age-related neural mechanisms of visual motion priming revealed by event-related brain potentials Y J Luo*, Y Jiang, R Parasuraman, The Catholic University of America, USA
4.20	Characterization of beta-Amyloid interactions with glycolipid receptors by surface plasmon resonance T Valdes-Gonzalez*, T Ido, Tohoku University, Japan: J Inagawa, Biacore, Japan
4.21	Plasma level of alpha-tocopherol (vitamin E) in patients with Alzheimer's disease L Crescibene*, M C Scornaienchi, A Bagalà, L Bastone, M Caracciolo, G Nicoletti; Institute of Experimental Medicine and Biotechnology, Italy
4.22	Relationships of oxidative stress, angiogenesis and Alzheimer's disease Y Fang*, M Hu, K Liu; Fudan University, PR China
4.23	Characterization of the neuronal Cdk5 activator homologue (Nck5ai) in mouse brain D-G Park, K-Y Lee*, The University of Calgary, Canada
4.24	SOD1 inhibition leads to inflammatory neuronal loss in hippocampal slice cultures S B Basu, S I Moskowitz, P J Bergold*; SUNY Downstate Medical Center, USA
4.25	New neuro-pathogens: the runaway antisense homology box peptides L Baranyi1*, I Farkas2, O Hidechika3, C R Alving1: 1Walter Reed Army Institute of Research, USA: 2Albert Szent-Györgyi Medical University, Hungary: 3Nagoya City University School of Medicine, USA
4.26	Increased ubiquitin staining in entorhinal cortex of aged Fischer/Norway hybrid rats is associated with impaired memory: a model for inflammation-related cognitive decline? J L Koch*, F Haun; NeuroDetective Inc, USA
4.27	Coagulation markers and vascular phenotypes in cognitive impairment and dementia V S Thomas*; University of Nebraska Medical Center, USA: S Giampaoli; Istituto Superiore di Sanita, Italy
5 - Clinical Mastars, Development of Substances with Potential Therapeutic Effects
1: Complement and Acute Phase Reactants 2: Microglial/Astroglial/Mononuclear Cell Physiology 3: Cytokines 4: Second Messenger and Oxidative Metabolism, Miscellaneous 5: Clinical Mastars, Development of Substances with Potential Therapeutic Effects
5.01	Ab 1-42 peptide increases, whereas pentoxifylline antagonizes, the source of inflammatory cytokines IFN-g and TNF-a by immune cells of patients with Alzheimer's Disease (AD) S B Solerte*, L Cravello, N Schifino, R Bonacasa, E Ferraria, M Fioravanti; University of Pavia, Italy
5.02	Antiphospholipid antibodies associated with Alzheimer's disease: data from the Italian Longitudinal Study on Ageing (ILSA) P Vanni, G Carlucci*, G Ciampi1, G Pracucci, L Pantoni, D Inzitari, et al; University of Florence, Italy: 1Santa Maria Annunziata Hospital, Italy
5.03	Ibuprofen reduces inflammation and Alzheimer pathology in a mouse model for AD G P Lim*, F Yang, T Chu, P Chen, W Beech, T Tran, et al; University of California Los Angeles and Greater Los Angeles VA Healthcare System, USA
5.04	Decreased L-tryptophan in patients with Alzheimer's disease B Widner, F Leblhuber, J Walli, D Fuchs*; University of Innsbruck and Wagner Jauregg Hospital, Austria
5.05	Neuroprotective effects of principles from Ginkgo biloba X-Y Li*, X-Z Zhu; Shanghai Institute of Materia Medica, PR China
5.06	Markers of inflammation and risk of dementia. The Rotterdam study M J Engelhart*, A Ruitenberg, J Meijer, A J Kiliaan, J C M Witteman, M M B Breteler; Erasmus Medical Centre Rotterdam, The Netherlands
5.07	Study of genes related to Alzheimer's disease and vascular disease F Ying*, X Xianhao, G Hong, P Dantao, W Shiguang, W Hong, et al; Beijing Hospital, PR China: Natl Center for Clinical Laboratory, PR China: Center Hospital of Jinan Railway Bureau, PR China
5.08	Colostrinin® - possibility of application in the treatment of Alzheimer's disease J Leszek*, A Kiejna; University of Wroclaw, Poland: M Janusz, A D Inglot, J Lisowski; Inst of Immunology and Experimental Therapy, Poland: J Georgiades, ReGen Biotech Limited, UK
5.09	The effect of chronic anti-inflammatory drug use on Alzheimer-type pathology in aging I R A Mackenzie*; Vancouver General Hospital, Canada: D G Munoz; London Health Sciences Centre
5.10	Impact of polymorphisms in genes involved in the inflammatory processes on Ab deposition in Alzheimer's disease brains E K Green1, J M Harris1, J C Lambert1, N J Craddock1, M C Chartier-Harlin2, D M A Mann3, T Iwatsubo4, C L Lendon1*; 1Univ of Birmingham, UK: 2INSERM 508, France: 3Univ of Manchester, UK: 4Univ of Tokyo, Japan
5.11	Estrogen and raloxifene inhibit neuroglial proliferation in vivo D-L Lei, J M Long, J M Hengemihle, D K Ingram, P R Mouton*, The Johns Hopkins University School of Medicine, USA
5.12	Is the diminution in brain ATP metabolism an initiating event of neuro-inflammatory mechanisms in Alzheimer's Disease? A Halbreich*; Université P & M Curie, France: M Roudier; Hôpital Charles Richet, France
5.13	Treatment of Alzheimer's disease with indomethacin: Design of a multicenter double-blind placebo-controlled clinical trial D de Jong*, R W M M Jansen, M M Verbeek, H P H Kremer; University Medical Centre Nijmegen, The Netherlands
5.14	Danthron attenuates beta-amyloid[25-35]-induced neurotoxicity in primary cortical cultures M B Wie*; Cheju National University, Korea: J Y Koh; Ulsan University, Korea: D K Song, Y H Kim, Hallym University, Korea

©1999 Elsevier Science Ltd
All rights reserved
Web design by Sparks